These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 9512108)

  • 21. Update on disease-modifying antirheumatic drugs in the treatment of systemic sclerosis.
    Lin AT; Clements PJ; Furst DE
    Rheum Dis Clin North Am; 2003 May; 29(2):409-26. PubMed ID: 12841302
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Interstitial lung disease in systemic sclerosis: current and future treatment.
    Giacomelli R; Liakouli V; Berardicurti O; Ruscitti P; Di Benedetto P; Carubbi F; Guggino G; Di Bartolomeo S; Ciccia F; Triolo G; Cipriani P
    Rheumatol Int; 2017 Jun; 37(6):853-863. PubMed ID: 28063071
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Vascular complications of scleroderma.
    Guiducci S; Giacomelli R; Cerinic MM
    Autoimmun Rev; 2007 Sep; 6(8):520-3. PubMed ID: 17854742
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Therapeutic targets in systemic sclerosis.
    Denton CP
    Arthritis Res Ther; 2007; 9 Suppl 2(Suppl 2):S6. PubMed ID: 17767744
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Systemic sclerosis - continuing progress in developing clinical measures of response.
    Furst D; Khanna D; Matucci-Cerinic M; Clements P; Steen V; Pope J; Merkel P; Foeldvari I; Seibold J; Pittrow D; Polisson R; Strand V
    J Rheumatol; 2007 May; 34(5):1194-200. PubMed ID: 17477486
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Localized and systemic scleroderma.
    Hawk A; English JC
    Semin Cutan Med Surg; 2001 Mar; 20(1):27-37. PubMed ID: 11308134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Systemic sclerosis--introductory lecture].
    Kaliterna DM; Radić M
    Reumatizam; 2010; 57(2):90-3. PubMed ID: 21875010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Vasoactive therapies in systemic sclerosis.
    Riemekasten G; Sunderkötter C
    Rheumatology (Oxford); 2006 Oct; 45 Suppl 3():iii49-51. PubMed ID: 16987836
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of agents for the treatment of systemic sclerosis.
    Herrick AL
    Expert Opin Investig Drugs; 2001 Jul; 10(7):1255-64. PubMed ID: 11772249
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Disease-modifying effects of long-term cyclic iloprost therapy in systemic sclerosis. A retrospective analysis and comparison with a control group.
    Airò P; Rossi M; Scarsi M; Danieli E; Grottolo A; Zambruni A
    Clin Exp Rheumatol; 2007; 25(5):722-7. PubMed ID: 18078620
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Old medications and new targeted therapies in systemic sclerosis.
    Nagaraja V; Denton CP; Khanna D
    Rheumatology (Oxford); 2015 Nov; 54(11):1944-53. PubMed ID: 25065013
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raynaud's phenomenon.
    Wigley FM; Flavahan NA
    Rheum Dis Clin North Am; 1996 Nov; 22(4):765-81. PubMed ID: 8923595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. EULAR recommendations for the treatment of systemic sclerosis: a report from the EULAR Scleroderma Trials and Research group (EUSTAR).
    Kowal-Bielecka O; Landewé R; Avouac J; Chwiesko S; Miniati I; Czirjak L; Clements P; Denton C; Farge D; Fligelstone K; Földvari I; Furst DE; Müller-Ladner U; Seibold J; Silver RM; Takehara K; Toth BG; Tyndall A; Valentini G; van den Hoogen F; Wigley F; Zulian F; Matucci-Cerinic M;
    Ann Rheum Dis; 2009 May; 68(5):620-8. PubMed ID: 19147617
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Emerging targets of disease-modifying therapy for systemic sclerosis.
    Volkmann ER; Varga J
    Nat Rev Rheumatol; 2019 Apr; 15(4):208-224. PubMed ID: 30796362
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prospects for improving outcomes in systemic sclerosis-related pulmonary hypertension.
    Thakkar V; Nikpour M; Stevens WM; Proudman SM
    Intern Med J; 2015 Mar; 45(3):248-54. PubMed ID: 25735576
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence-based management of systemic sclerosis: Navigating recommendations and guidelines.
    Pellar RE; Pope JE
    Semin Arthritis Rheum; 2017 Jun; 46(6):767-774. PubMed ID: 28088339
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Determinants of morbidity and mortality of systemic sclerosis in Canada.
    Al-Dhaher FF; Pope JE; Ouimet JM
    Semin Arthritis Rheum; 2010 Feb; 39(4):269-77. PubMed ID: 18706680
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Scleroderma--clinical and pathological advances.
    Denton CP; Black CM
    Best Pract Res Clin Rheumatol; 2004 Jun; 18(3):271-90. PubMed ID: 15158741
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Is there evidence for vasculitis in systemic sclerosis?
    Saketkoo LA; Distler O
    Curr Rheumatol Rep; 2012 Dec; 14(6):516-25. PubMed ID: 23065452
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevalence and risk factors for left ventricular diastolic dysfunction in a scleroderma cohort.
    Vemulapalli S; Cohen L; Hsu V
    Scand J Rheumatol; 2017 Jul; 46(4):281-287. PubMed ID: 27635465
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.